MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate

被引：14
|
作者：
Warakaulle, DR [1 ]
Gleeson, F [1 ]
机构：
[1] Churchill Hosp, Dept Radiol, Oxford OX3 7LJ, England
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2006年 / 186卷 / 02期
关键词：
CT; gastrointestinal imaging; gastrointestinal stromal tumors; imatinib mesylate; oncologic imaging;
D O I：
10.2214/AJR.04.1516
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OBJECTIVE. Our objective was to determine the MDCT appearance of gastrointestinal stromal tumors (GISTs) after treatment with imatinib mesylate. CONCLUSION. Cystic changes within primary and metastatic GISTs seen on MDCT in patients after imatinib mesylate therapy are evidence of disease response. Calcification may also occur in lesions that respond to therapy.
引用
收藏
页码：510 / 515
页数：6
相关论文
共 50 条
  • [21] Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
    Kanda, Tatsuo
    Nishida, Toshirou
    Wada, Norihito
    Kobayashi, Osamu
    Yamamoto, Masakazu
    Sawaki, Akira
    Boku, Narikazu
    Koseki, Masato
    Doi, Toshihiko
    Toh, Yasushi
    Kakeji, Yoshihiro
    Sugiyama, Toshiro
    Komatsu, Yoshito
    Kikuchi, Shojiro
    Ogoshi, Kyoji
    Katai, Hitoshi
    Miyachi, Kazuhito
    Hirota, Seiichi
    Ohtsu, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (01) : 38 - 45
  • [22] Nilotinib in Advanced Gastrointestinal Stromal Tumors after Imatinib and Sunitinib Therapy
    Dizdar, Omer
    Yalcin, Suayib
    HEPATO-GASTROENTEROLOGY, 2011, 58 (112) : 2012 - 2014
  • [23] Prognostic values of DLK1 for surgery and imatinib mesylate adjuvant therapy in gastrointestinal stromal tumors
    Xu, Jia
    Wang, Ming
    Zhang, Zizhen
    Zhao, Wenyi
    Wang, Chaojie
    Tu, Lin
    Zhang, Yeqian
    Cao, Hui
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (11): : 2700 - 2712
  • [24] Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients
    Tang, Lei
    Zhang, Xiao-Peng
    Sun, Ying-Shi
    Shen, Lin
    Li, Jian
    Qi, Li-Ping
    Cui, Yong
    RADIOLOGY, 2011, 258 (03) : 729 - 738
  • [25] Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
    Gauden, Ruth
    Gauden, Stan
    CASE REPORTS IN ONCOLOGY, 2011, 4 (01): : 204 - 210
  • [26] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Sith Phongkitkarun
    Cholada Phaisanphrukkun
    Janjira Jatchavala
    Ekaphop Sirachainan
    World Journal of Gastroenterology, 2008, (06) : 892 - 898
  • [27] Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty
    Yildiz, Ibrahim
    Mandel, Nil M.
    Demir, Gokhan
    Ozguroglu, Mustafa
    Toptas, Tayfur
    Buyukunal, Evin
    Serdengecti, Suheyla
    ANNALS OF ONCOLOGY, 2006, 17 : 164 - 164
  • [28] Assessment of gastrointestinal stromal tumors with computed tomography following treatment with imatinib mesylate
    Phongkitkarun, Sith
    Phaisanphrukkun, Cholada
    Jatchavala, Janjira
    Sirachainan, Ekaphop
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (06) : 892 - 898
  • [29] Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
    Ksienski, Doran
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 365 - 379
  • [30] Survival benefit of imatinib mesylate on patients with advanced gastrointestinal stromal tumors (GIST)
    Lin, M. T.
    Hu, T. H.
    Lin, J. W.
    Wang, C. C.
    Rau, K. M.
    Changchien, C. S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A44 - A44
12345